The research involved teams from the University of Victoria, Monash University, and Vancouver Island University.
The study examined a rat model designed to mimic the types of injuries commonly reported in IPV survivors: repeated mild traumatic brain injury and short episodes of non-fatal strangulation. Female rats received daily head impacts followed by 90-second strangulation events for five consecutive days, then were allowed a 16-week recovery period to mirror the chronic symptoms often seen in humans.
After the recovery period, the animals were given either a single dose of psilocybin (1 mg/kg) or saline. Those that received psilocybin showed notable improvements. Anxiety-like behaviors normalized in the elevated plus-maze, measures of motivation improved through increased sucrose preference, and cognitive performance strengthened in both spatial-memory and reversal-learning tests. These benefits disappeared when rats were pre-treated with a 5-HT2A receptor–blocking compound, indicating that psilocybin’s effects were driven by this serotonin receptor.
The brain analysis aligned with the behavioral results. Injured rats that received saline had more activated microglia—an indicator of neuroinflammation—in the dorsal hippocampus, as well as fewer reelin-positive cells linked to neuroplasticity. Those alterations were not present in the psilocybin-treated group.
Taken together, the findings suggest that psilocybin’s antidepressant-like, pro-cognitive, and anti-inflammatory actions may help counter long-term effects of repetitive IPV-related brain injury, and that the 5-HT2A receptor plays a key role in those benefits.
Hellbound and Down 